Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
D1AMOND Tourette’s Disorder Ecopipam Randomized Withdrawal Study
2023-503494-38-00Phase 3Completed
- Sponsor
- Emalex Biosciences
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial in Tourette syndrome (TS) comparing Ecopipam maintenance with Placebo randomized withdrawal (2 arms). Primary endpoint: Time from randomization to relapse in subjects aged ≥6 and <18 years. Started Jun 2023; status: completed.
02
Drugs
ecopipam
03
Conditions
Tourette syndrome (TS)
Beyond the preview
Go deeper on 2023-503494-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503494-38-00.